Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Payers Give High Marks for “Bold” Pricing Reform, but Not Happy with PMP
February 8, 2018
- Chuikyo Submits Recommendation for FY2018 Reimbursement Policy Reform, Drug Pricing Package Enshrined
February 8, 2018
- MHLW Notifies of Revisions of Ministerial Ordinances to Prevent Distribution of Counterfeit Drugs
February 7, 2018
- Japan’s 1st Herceptin Biosimilar Clears MHLW Panel, Now in Line for March Approval for Gastric Cancer
February 5, 2018
- MHLW Panel Backs “Sakigake” Influenza Drug; Possibility of Accelerated Approval and Listing Unclear
February 5, 2018
- MHLW Cautions on Hepatitis E Virus Infection due to Blood Products for Transfusion
February 2, 2018
- MHLW Panel Calls for Single-Product, Single-Price Transactions for Blood Products
February 2, 2018
- Proper Use of Ethical Moisturizing Agents Added to Supplementary Opinion for FY2018 Reimbursement Reform: Chuikyo
February 1, 2018
- Drug Pricing Reform Draws Mixed Opinions: Public Comments
February 1, 2018
- Drug Makers Looking to Adopt Continuous Manufacturing, Anticipating 30-40% Lower Production Costs: PMDA Official
January 31, 2018
- MHLW to Create Framework for Announcing Results of Clinical Research in Tandem with Enforcement of Clinical Research Law
January 29, 2018
- Chuikyo to Continue Discussions on Drug Pricing Reform “After Verifying Impact on Stakeholders”; Further Discussions on Essential Drugs
January 29, 2018
- Chuikyo Discusses Hirudoid, Gx at 2nd Review Round for FY2018 Fee Schedule Revision
January 29, 2018
- MHLW Panel Backs Novo’s Semaglutide after Recommendation Hold
January 29, 2018
- MHLW’s Drug Distribution Guidelines Issued for Enforcement in April
January 26, 2018
- MHLW Reiterates Caution over Tagrisso Use after Opdivo Treatment
January 26, 2018
- IPRP to Hold First Meeting in June in Japan, May Take up Harmonization of Regulations on Regenerative Medicine Products
January 26, 2018
- Chuikyo Enters Final Review of FY2018 Fee Schedule Revision; Recommendation Due Out Feb. 7
January 25, 2018
- MHLW to Launch New Project to Strengthen Generic Drug Use in Around 10 “Priority Prefectures” Aiming at 80% Volume Share Target
January 25, 2018
- Japan Govt to Halt R&D Tax Break for Small Spender Companies: PM Abe
January 24, 2018
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…